{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:03:59Z","timestamp":1780452239568,"version":"3.54.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007709","name":"Michigan State University","doi-asserted-by":"publisher","award":["CVM Endowed Research Funds"],"award-info":[{"award-number":["CVM Endowed Research Funds"]}],"id":[{"id":"10.13039\/100007709","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["T32OD011127"],"award-info":[{"award-number":["T32OD011127"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4132-0","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T01:08:18Z","timestamp":1519866498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies"],"prefix":"10.1186","volume":"18","author":[{"given":"Marilia","family":"Takada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Parys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmalena","family":"Gregory-Bryson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Vilar Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Kiupel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-1279","authenticated-orcid":false,"given":"Vilma","family":"Yuzbasiyan-Gurkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"issue":"4","key":"4132_CR1","first-page":"376","volume":"5","author":"ES Jaffe","year":"1988","unstructured":"Jaffe ES. Histiocytoses of lymph nodes: biology and differential diagnosis. Semin Diagn Pathol. 1988;5(4):376\u201390.","journal-title":"Semin Diagn Pathol"},{"key":"4132_CR2","volume-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001."},{"issue":"6","key":"4132_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00000372-199212000-00004","volume":"14","author":"C Soria","year":"1992","unstructured":"Soria C, Orradre JL, Garcia-Almagro D, Martinez B, Algara P, Piris MA. True histiocytic lymphoma (monocytic sarcoma). Am J Dermatopathol. 1992;14(6):511\u20137.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"4132_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/modpathol.3800346","volume":"18","author":"JA Vos","year":"2005","unstructured":"Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18(5):693\u2013704.","journal-title":"Mod Pathol"},{"key":"4132_CR5","doi-asserted-by":"crossref","unstructured":"Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N. Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;88(2):253\u201371.","DOI":"10.1016\/j.critrevonc.2013.05.006"},{"issue":"8","key":"4132_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/ajh.20852","volume":"82","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, et al. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol. 2007;82(8):725\u20138.","journal-title":"Am J Hematol"},{"issue":"10","key":"4132_CR7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ajh.20913","volume":"82","author":"MH Abidi","year":"2007","unstructured":"Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol. 2007;82(10):932\u20133.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"4132_CR8","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/jhered\/esp039","volume":"100","author":"J Abadie","year":"2009","unstructured":"Abadie J, Hedan B, Cadieu E, De Brito C, Devauchelle P, Bourgain C, et al. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. J Hered. 2009;100(Suppl 1):S19\u201327.","journal-title":"J Hered"},{"issue":"2","key":"4132_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1476-5829.2008.00181.x","volume":"7","author":"J Dobson","year":"2009","unstructured":"Dobson J, Hoather T, McKinley TJ, Wood JL. Mortality in a cohort of flat-coated retrievers in the UK. Vet Comp Oncol. 2009;7(2):115\u201321.","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"4132_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.tvjl.2013.09.062","volume":"198","author":"SA Erich","year":"2013","unstructured":"Erich SA, Rutteman GR, Teske E. Causes of death and the impact of histiocytic sarcoma on the life expectancy of the Dutch population of Bernese mountain dogs and flat-coated retrievers. Vet J. 2013;198(3):678\u201383.","journal-title":"Vet J"},{"issue":"5","key":"4132_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1354\/vp.43-5-632","volume":"43","author":"PF Moore","year":"2006","unstructured":"Moore PF, Affolter VK, Vernau W. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet Pathol. 2006;43(5):632\u201345.","journal-title":"Vet Pathol"},{"issue":"10","key":"4132_CR12","first-page":"1041","volume":"48","author":"AK Fulmer","year":"2007","unstructured":"Fulmer AK, Mauldin GE. Canine histiocytic neoplasia: an overview. Can Vet J. 2007;48(10):1041\u20133.","journal-title":"Can Vet J"},{"key":"4132_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1471-2407-11-201","volume":"11","author":"B Hedan","year":"2011","unstructured":"Hedan B, Thomas R, Motsinger-Reif A, Abadie J, Andre C, Cullen J, et al. Molecular cytogenetic characterization of canine histiocytic sarcoma: a spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer. 2011;11:201.","journal-title":"BMC Cancer"},{"issue":"7","key":"4132_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1055-9965.EPI-12-0190-T","volume":"21","author":"AL Shearin","year":"2012","unstructured":"Shearin AL, Hedan B, Cadieu E, Erich SA, Schmidt EV, Faden DL, et al. The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer. Cancer Epidemiol. 2012;21(7):1019\u201327.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"4132_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1354\/vp.39-1-74","volume":"39","author":"VK Affolter","year":"2002","unstructured":"Affolter VK, Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol. 2002;39(1):74\u201383.","journal-title":"Vet Pathol"},{"issue":"6","key":"4132_CR16","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1939-1676.2010.0588.x","volume":"24","author":"KM Rassnick","year":"2010","unstructured":"Rassnick KM, Moore AS, Russell DS, Northrup NC, Kristal O, Bailey DB, et al. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Intern Med. 2010;24(6):1528\u201331.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"4132_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1354\/vp.39-1-66","volume":"39","author":"LE Craig","year":"2002","unstructured":"Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Vet Pathol. 2002;39(1):66\u201373.","journal-title":"Vet Pathol"},{"issue":"2","key":"4132_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1476-5810.2006.00090.x","volume":"4","author":"J Fidel","year":"2006","unstructured":"Fidel J, Schiller I, Hauser B, Jausi Y, Rohrer-Bley C, Roos M, et al. Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998-march 2005). Vet Comp Oncol. 2006;4(2):63\u201374.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"4132_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","volume":"21","author":"KA Skorupski","year":"2007","unstructured":"Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007;21(1):121\u20136.","journal-title":"J Vet Intern Med"},{"key":"4132_CR20","doi-asserted-by":"crossref","unstructured":"Higuchi T, Dervisis N, Kitchell B. Efficacy of doxorubicin for histiocytic sarcoma in dogs. Abstracts presented at the 30th Annual VCS Conference, San Diego, CA, USA, 29 October-1 November 2010. Vet Comp Oncol. 2010;9:e1-e49.","DOI":"10.1111\/j.1476-5829.2010.00252.x"},{"issue":"10","key":"4132_CR21","first-page":"1789","volume":"3","author":"S Visonneau","year":"1997","unstructured":"Visonneau S, Cesano A, Tran T, Jeglum KA, Santoli D. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Clin Cancer Res. 1997;3(10):1789\u201397.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4132_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s002800050591","volume":"39","author":"DM Vail","year":"1997","unstructured":"Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol. 1997;39(5):410\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4132_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1939-1676.2004.tb00164.x","volume":"18","author":"VJ Poirier","year":"2004","unstructured":"Poirier VJ, Hershey AE, Burgess KE, Phillips B, Turek MM, Forrest LJ, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med. 2004;18(2):219\u201322.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"4132_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/vco.12056","volume":"13","author":"CL Mariani","year":"2013","unstructured":"Mariani CL, Schubert TA, House RA, Wong MA, Hopkins AL, Barnes Heller HL, et al. Frameless stereotactic radiosurgery for the treatment of primary intracranial tumours in dogs. Vet Comp Oncol. 2013;13(4):409\u201323.","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"4132_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tvjl.2012.12.016","volume":"196","author":"K Ito","year":"2013","unstructured":"Ito K, Kuroki S, Kobayashi M, Ono K, Washizu T, Bonkobara M. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells. Vet J. 2013;196(3):536\u201340.","journal-title":"Vet J"},{"issue":"1","key":"4132_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.tvjl.2011.01.001","volume":"191","author":"DH Thamm","year":"2012","unstructured":"Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, et al. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. Vet J. 2012;191(1):131\u20134.","journal-title":"Vet J"},{"issue":"7","key":"4132_CR27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2460\/ajvr.69.7.938","volume":"69","author":"WC Kisseberth","year":"2008","unstructured":"Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. Am J Vet Res. 2008;69(7):938\u201345.","journal-title":"Am J Vet Res"},{"issue":"7\u20138","key":"4132_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000340066","volume":"35","author":"K Schlick","year":"2012","unstructured":"Schlick K, Aigelsreiter A, Pichler M, Reitter S, Neumeister P, Hoefler G, et al. Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases. Onkologie. 2012;35(7\u20138):447\u201350.","journal-title":"Onkologie"},{"key":"4132_CR29","doi-asserted-by":"crossref","unstructured":"Takada M, Parys M, Gregory-Bryson E, Yuzbasiyan-Gurkan V. A novel canine histiocytic sarcoma cell line provides a potential path to effective treatments with relevance for translational and comparative studies in humans. Cancer Res. 2014;74(19 Supplement):3931.","DOI":"10.1158\/1538-7445.AM2014-3931"},{"issue":"1","key":"4132_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2460\/javma.239.1.90","volume":"239","author":"SL Klahn","year":"2011","unstructured":"Klahn SL, Kitchell BE, Dervisis NG. Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma. J Am Vet Med Assoc. 2011;239(1):90\u20136.","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"4132_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jvim.12059","volume":"27","author":"L van Kuijk","year":"2013","unstructured":"van Kuijk L, van Ginkel K, de Vos JP, Brearley MJ, Butinar J, Gielen I, et al. Peri-articular histiocytic sarcoma and previous joint disease in Bernese Mountain dogs. J Vet Intern Med. 2013;27(2):293\u20139.","journal-title":"J Vet Intern Med"},{"key":"4132_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000188796","volume":"18","author":"L Skoog","year":"2009","unstructured":"Skoog L, Tani E. Histiocytic and dendritic neoplasms. Monogr Clin Cytol. 2009;18:56\u20139.","journal-title":"Monogr Clin Cytol"},{"issue":"1","key":"4132_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/ajcp\/102.1.45","volume":"102","author":"AF Lauritzen","year":"1994","unstructured":"Lauritzen AF, Delsol G, Hansen NE, Horn T, Ersboll J, Hou-Jensen K, et al. Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study. Am J Clin Pathol. 1994;102(1):45\u201354.","journal-title":"Am J Clin Pathol"},{"issue":"2\u20133","key":"4132_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jcpa.2012.06.009","volume":"148","author":"Y Kato","year":"2013","unstructured":"Kato Y, Murakami M, Hoshino Y, Mori T, Maruo K, Hirata A, et al. The class a macrophage scavenger receptor CD204 is a useful immunohistochemical marker of canine histiocytic sarcoma. J Comp Pathol. 2013;148(2\u20133):188\u201396.","journal-title":"J Comp Pathol"},{"issue":"10","key":"4132_CR35","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.4049\/jimmunol.178.10.6307","volume":"178","author":"C Casals","year":"2007","unstructured":"Casals C, Barrachina M, Serra M, Lloberas J, Celada A. Lipopolysaccharide up-regulates MHC class II expression on dendritic cells through an AP-1 enhancer without affecting the levels of CIITA. J Immunol. 2007;178(10):6307\u201315.","journal-title":"J Immunol"},{"key":"4132_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4757-9966-8_25","volume":"417","author":"K Mahnke","year":"1997","unstructured":"Mahnke K, Becher E, Ricciardi-Castagnoli P, Luger TA, Schwarz T, Grabbe S. CD14 is expressed by subsets of murine dendritic cells and upregulated by lipopolysaccharide. Adv Exp Med Biol. 1997;417:145\u201359.","journal-title":"Adv Exp Med Biol"},{"issue":"7252","key":"4132_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nature08118","volume":"460","author":"I Zanoni","year":"2009","unstructured":"Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature. 2009;460(7252):264\u20138.","journal-title":"Nature"},{"issue":"5","key":"4132_CR38","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/eji.200425726","volume":"35","author":"D Bimczok","year":"2005","unstructured":"Bimczok D, Sowa EN, Faber-Zuschratter H, Pabst R, Rothkotter HJ. Site-specific expression of CD11b and SIRPalpha (CD172a) on dendritic cells: implications for their migration patterns in the gut immune system. Eur J Immunol. 2005;35(5):1418\u201327.","journal-title":"Eur J Immunol"},{"issue":"5","key":"4132_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1095\/biolreprod.112.101121","volume":"87","author":"N Mansouri-Attia","year":"2012","unstructured":"Mansouri-Attia N, Oliveira LJ, Forde N, Fahey AG, Browne JA, Roche JF, et al. Pivotal role for monocytes\/macrophages and dendritic cells in maternal immune response to the developing embryo in cattle. Biol Reprod. 2012;87(5):123.","journal-title":"Biol Reprod"},{"issue":"52","key":"4132_CR40","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.1016\/j.vaccine.2012.10.043","volume":"30","author":"T Kaisho","year":"2012","unstructured":"Kaisho T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine. 2012;30(52):7652\u20137.","journal-title":"Vaccine"},{"issue":"2","key":"4132_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.bbrc.2013.11.112","volume":"443","author":"F Schutz","year":"2014","unstructured":"Schutz F, Hackstein H. Identification of novel dendritic cell subset markers in human blood. Biochem Biophys Res Commun. 2014;443(2):453\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"4132_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1600-065X.2007.00552.x","volume":"219","author":"A Savina","year":"2007","unstructured":"Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev. 2007;219:143\u201356.","journal-title":"Immunol Rev"},{"issue":"6","key":"4132_CR43","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2144\/000112001","volume":"39","author":"A Beletskii","year":"2005","unstructured":"Beletskii A, Cooper M, Sriraman P, Chiriac C, Zhao L, Abbot S, et al. High-throughput phagocytosis assay utilizing a pH-sensitive fluorescent dye. BioTechniques. 2005;39(6):894\u20137.","journal-title":"BioTechniques"},{"issue":"2","key":"4132_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nprot.2007.25","volume":"2","author":"CL Morton","year":"2007","unstructured":"Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2(2):247\u201350.","journal-title":"Nat Protoc"},{"issue":"3","key":"4132_CR45","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/0300985817690211","volume":"54","author":"A Thongtharb","year":"2017","unstructured":"Thongtharb A, Uchida K, Chambers JK, Nakayama H. Variations in histiocytic differentiation of cell lines from canine cerebral and articular histiocytic sarcomas. Vet Pathol. 2017;54(3):395\u2013404.","journal-title":"Vet Pathol"},{"key":"4132_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.rvsc.2015.02.003","volume":"99","author":"H Yamazaki","year":"2015","unstructured":"Yamazaki H, Takagi S, Hosoya K, Okumura M. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models. Res Vet Sci. 2015;99:137\u201344.","journal-title":"Res Vet Sci"},{"issue":"12","key":"4132_CR47","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1292\/jvms.68.1343","volume":"68","author":"D Azakami","year":"2006","unstructured":"Azakami D, Bonkobara M, Washizu T, Iida A, Kondo M, Kato R, et al. Establishment and biological characterization of canine histiocytic sarcoma cell lines. J Vet Med Sci. 2006;68(12):1343\u20136.","journal-title":"J Vet Med Sci"},{"issue":"12","key":"4132_CR48","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1182\/blood.V87.12.5207.bloodjournal87125207","volume":"87","author":"RA Soslow","year":"1996","unstructured":"Soslow RA, Davis RE, Warnke RA, Cleary ML, Kamel OW. True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood. 1996;87(12):5207\u201312.","journal-title":"Blood"},{"issue":"1","key":"4132_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2559.2002.01418.x","volume":"41","author":"SA Pileri","year":"2002","unstructured":"Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the international lymphoma study group based on 61 cases. Histopathology. 2002;41(1):1\u201329.","journal-title":"Histopathology"},{"issue":"35","key":"4132_CR50","doi-asserted-by":"publisher","first-page":"e117-21","DOI":"10.1200\/JCO.2013.49.0078","volume":"32","author":"D Michonneau","year":"2014","unstructured":"Michonneau D, Kaltenbach S, Derrieux C, Trinquand A, Brouzes C, Gibault L, et al. BRAFV600E mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol. 2014;32(35):e117-21.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4132_CR51","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","volume":"28","author":"JL Hornick","year":"2004","unstructured":"Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28(9):1133\u201344.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"4132_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1476-5829.2011.00274.x","volume":"10","author":"SD Hafeman","year":"2012","unstructured":"Hafeman SD, Varland D, Dow SW. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol. 2012;10(1):44\u201356.","journal-title":"Vet Comp Oncol"},{"issue":"11","key":"4132_CR53","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","volume":"29","author":"M Steinberg","year":"2007","unstructured":"Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29(11):2289\u2013308.","journal-title":"Clin Ther"},{"issue":"5","key":"4132_CR54","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"issue":"24","key":"4132_CR55","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"4132_CR56","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23624","volume":"89","author":"O Benjamini","year":"2014","unstructured":"Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89(3):282\u20137.","journal-title":"Am J Hematol"},{"issue":"5","key":"4132_CR57","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10637-014-0106-5","volume":"32","author":"A Spreafico","year":"2014","unstructured":"Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investig New Drugs. 2014;32(5):1005\u201316.","journal-title":"Investig New Drugs"},{"issue":"13\u201314","key":"4132_CR58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.clinbiochem.2014.05.066","volume":"47","author":"Y Safdari","year":"2014","unstructured":"Safdari Y, Khalili M, Farajnia S, Asgharzadeh M, Yazdani Y, Sadeghi M. Recent advances in head and neck squamous cell carcinoma - a review. Clin Biochem. 2014;47(13\u201314):1195\u2013202.","journal-title":"Clin Biochem"},{"issue":"16","key":"4132_CR59","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1212\/WNL.0000000000000880","volume":"83","author":"A Idbaih","year":"2014","unstructured":"Idbaih A, Mokhtari K, Emile JF, Galanaud D, Belaid H, de Bernard S, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology. 2014;83(16):1478\u201380.","journal-title":"Neurology"},{"issue":"10","key":"4132_CR60","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.exphem.2007.06.005","volume":"35","author":"KV Gleixner","year":"2007","unstructured":"Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol. 2007;35(10):1510\u201321.","journal-title":"Exp Hematol"},{"issue":"3","key":"4132_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1476-5829.2011.00261.x","volume":"10","author":"C Robat","year":"2012","unstructured":"Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, et al. Safety evaluation of combination vinblastine and toceranib phosphate (palladia(R)) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012;10(3):174\u201383.","journal-title":"Vet Comp Oncol"},{"issue":"10","key":"4132_CR62","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813\u201323.","journal-title":"Nat Rev Cancer"},{"issue":"7391","key":"4132_CR63","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137.","journal-title":"Nature"},{"issue":"2","key":"4132_CR64","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/vco.12192","volume":"15","author":"JS Fowles","year":"2016","unstructured":"Fowles JS, Dailey DD, Gustafson DL, Thamm DH, Duval DL. The Flint animal cancer center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine. Vet Comp Oncol. 2016;15(2):481\u201392.","journal-title":"Vet Comp Oncol"},{"issue":"5","key":"4132_CR65","first-page":"766","volume":"87","author":"F Doriano","year":"2014","unstructured":"Doriano F. 25 years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol. 2014;87(5):766\u201375.","journal-title":"Mol Pharmacol"},{"issue":"14","key":"4132_CR66","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1021\/jm9906116","volume":"43","author":"L Sun","year":"2000","unstructured":"Sun L, Tran N, Liang C, Hubbard S, Tang F, Lipson K, et al. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1\/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J Med Chem. 2000;43(14):2655\u201363.","journal-title":"J Med Chem"},{"issue":"3","key":"4132_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm1003","volume":"10","author":"EA Harrington","year":"2004","unstructured":"Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10(3):262\u20137.","journal-title":"Nat Med"},{"issue":"7","key":"4132_CR68","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"4132_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF00434350","volume":"14","author":"FY Lee","year":"1985","unstructured":"Lee FY, Workman P, Roberts JT, Bleehen NM. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemother Pharmacol. 1985;14(2):125\u201331.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4132_CR70","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM199403103301007","volume":"330","author":"A Saven","year":"1994","unstructured":"Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med. 1994;330(10):691\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"4132_CR71","doi-asserted-by":"publisher","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","volume":"4","author":"P Dubreuil","year":"2009","unstructured":"Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258.","journal-title":"PLoS One"},{"issue":"3","key":"4132_CR72","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","volume":"61","author":"AV Kamath","year":"2008","unstructured":"Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008;61(3):365\u201376.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4132_CR73","unstructured":"Scientific discussion for the approval of Erlotinib [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000618\/WC500033991.pdf\n                    \n                  ]. Accessed 28 Feb 2017."},{"key":"4132_CR74","unstructured":"Assessment report for Iressa [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001016\/WC500036361.pdf\n                    \n                  ]. Accessed 28 Feb 2017."},{"key":"4132_CR75","unstructured":"Scientific discussion for the approval of Imatinib [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000406\/WC500022203.pdf\n                    \n                  ]. Accessed 28 Feb 2017."},{"issue":"6","key":"4132_CR76","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1939-1676.2008.0190.x","volume":"22","author":"KA Hahn","year":"2008","unstructured":"Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008;22(6):301\u20139.","journal-title":"J Vet Intern Med"},{"key":"4132_CR77","unstructured":"Scientific discussion for the approval of Nilotinib [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000798\/WC500034398.pdf\n                    \n                  ]. Accessed 28 Feb 2017."},{"issue":"4","key":"4132_CR78","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2460\/ajvr.67.4.633","volume":"67","author":"R Zavodovskaya","year":"2006","unstructured":"Zavodovskaya R, Liao AT, Jones CL, Yip B, Chien MB, Moore PF, et al. Evaluation of dysregulation of the receptor tyrosine kinases kit, Flt3, and met in histiocytic sarcomas of dogs. Am J Vet Res. 2006;67(4):633\u201341.","journal-title":"Am J Vet Res"},{"issue":"4","key":"4132_CR79","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","volume":"49","author":"B Blanchet","year":"2009","unstructured":"Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49(4):1109\u201314.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"4132_CR80","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4132_CR81","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-010-1318-9","volume":"67","author":"AM Traynor","year":"2011","unstructured":"Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, et al. Phase I dose escalation study of MK-0457, a novel aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;67(2):305\u201314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4132_CR82","unstructured":"Scientific discussion for the approval of Cladribine [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000504\/WC500041660.pdf\n                    \n                  ]. Accessed 28 Feb 2017."},{"issue":"3","key":"4132_CR83","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1939-1676.2010.0496.x","volume":"24","author":"DL Gustafson","year":"2010","unstructured":"Gustafson DL, Thamm DH. Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. J Vet Intern Med. 2010;24(3):579\u201386.","journal-title":"J Vet Intern Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4132-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:22:29Z","timestamp":1589462549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4132-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4132"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4132-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"assertion":[{"value":"10 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The xenograft study described in the present paper was approved by the Michigan State University Institutional Animal Care and Use Committee (IACUC) (AUF# 07\/12\u2013127-00). Tumor tissue was used to establish the cell line from a client owned dog at post-mortem examination, with owner\u2019s written consent. The use of left over specimens was approved by IACUC, through an IACUC exemption form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"237"}}